City Therapeutics Stock
CTYNASDAQCity Therapeutics Inc., HealthcareISIN US1787821081
58Score 58 out of 100, Neutral
Price and Trend
39 / 100
Price history
−27% in one yearThe chart shows daily closes over 13 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 21% below it.
Since November 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 43).
The price is 28% below its 52-week high. Largest decline in 13 years: 52% (August 2016 to March 2020).
Chart figures for advanced users
- SMA 50$22.32
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$23.34
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)43
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$12.50
- The lowest closing price of the last twelve months.
- Resistance$25.65
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- City Therapeutics Inc. belongs to the Biotechnology industry (United States) and, with a market value of $979.67M, is number 185 of 277 companies in its industry on MEQIRI.
- In fiscal 2019 it reported revenue of $8.16B (down 4% year on year) and earnings of $1.83B (up 9.7%).
- MEQIRI Score 58 out of 100 (Neutral): rank 281 of 686 in Healthcare, median 53.
In Plain Words
The numbers on this page in plain words, written by an AI
Strengths
- Consistently ProfitableProfit in all 10 fiscal years from 2010 to 2019.Fundamentals 91
- High MarginNet margin 22.4% over the last 12 months, Biotechnology median −80.8%.Profitability 82
- Earnings Turn into CashFree cash flow 121% of earnings over the last 12 months.Fundamentals 91
Weaknesses
- Volatile Share PriceVolatility 68% a year over the last 12 months.Stability 62
Its standout strengths are fundamentals and profitability, while growth and momentum hold the score back.
Daily figure as of 20 Nov 2026
How the score is calculatedScore Overview
Score since yesterday from 56 to 58.
Fundamentals are strong, with stable profits and strong cash generation.
Score History
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation Signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany Performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2020, revenue fell 22.4% on the twelve months before. Revenue has stayed largely stable since 2005.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2019: gross 70%, operating 35%, net 22%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
Sector Comparison
686 rated companies in Healthcare
- This company
- 58
- Sector median
- 53
Categories Against the Sector MedianMedian of 686 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
ETFs That Hold City Therapeutics
Held by 2 of the 100 largest US ETFs. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Vanguard Extended Market ETFVXF | 0.00% | 0.05% | $30.2B |
| Vanguard Morningstar Total Stock Market ETFVTI | 0.00% | 0.03% | $689.3B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data Status and Sources
- Score
- Daily value of 20 Nov 2026, recalculated nightly
- Price
- Closing price of 19 Nov 2026
- Latest annual report
- Fiscal year 2019, period end 31 Dec 2019
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory Disclosures for This Rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 29 Feb 2020)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
